소마젠

950200KOSDAQ그외 기타 전문, 과학 및 기술 서비스업

40.0 / 100

Reference Date: 2026-04-13

Financial Score12.5 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Slightly down 4.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

SomaGen provides diverse genomic analysis services, including NGS, CES, single-cell analysis, and proteomics, collaborating with institutions like the US NIH and global pharmaceutical companies through a B2B model, establishing a strong presence in the North American market. It also expands into the B2C sector with DTC genetic testing and microbiome analysis services, leveraging partnerships with companies such as 10x Genomics and Olink Proteomics to enhance its technological capabilities.

Number of Employees

88people

Average Salary

78.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 59.134.0Point

PBR

—Industry Average 1.943.5Point

ROE

-15.09Industry Average 1.530.0Point

Well below industry avg

Debt Ratio

33.35Industry Average 16.090.0Point

2.1x industry avg (risky)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲29.7% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲8.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -15.9% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (17%, downtrend)

Current 3,335Won52-week high 4,12552-week low 3,165

1-month return2.0Point

1m -4.44% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral정기주주총회결과2026-03-31
Neutral[기재정정]주주총회소집공고2026-03-24
Neutral사업보고서 (2025.12)2026-03-23
Neutral감사보고서제출2026-03-23